Diagnostic importance of CD179a/b as markers of precursor B-cell lymphoblastic lymphoma

Department of Developmental Biology, National Research Institute for Child Health and Development, Japan.
Modern Pathology (Impact Factor: 6.19). 05/2004; 17(4):423-9. DOI: 10.1038/modpathol.3800079
Source: PubMed


Surrogate light chains consisting of VpreB (CD179a) and lambda5 (CD179b) are expressed in precursor B cells lacking a complete form of immunoglobulin and are thought to act as substitutes for conventional light chains. Upon differentiation to immature and mature B cells, CD179a/b disappear and are replaced with conventional light chains. Thus, these molecules may be useful as essential markers of precursor B cells. To examine the expression of the surrogate light-chain components CD179a and CD179b in precursor B-cell lymphoblastic lymphoma, we analyzed tissue sections using immunohistochemistry techniques. Among a number of monoclonal antibodies for the surrogate light chains, VpreB8 and SL11 were found to detect CD179a and CD179b, respectively, in acetone-fixed fresh frozen sections. Moreover, we also observed VpreB8 staining in formalin-fixed, paraffin-embedded sections. Using these antibodies, we found that CD179a/b were specifically expressed in precursor B-cell lymphoblastic lymphomas, but not in mature B-cell lymphomas in childhood. Furthermore, other pediatric tumors that must be included in a differential diagnosis of precursor B-cell lymphoblastic lymphoma, including precursor T-cell lymphoblastic lymphoma, extramedullary myeloid tumors, and Ewing sarcoma, were also negative for both CD179a and CD179b. Our data indicate that CD179a and CD179b may be important markers for the immunophenotypic diagnosis of precursor B-cell lymphoblastic lymphomas.

Download full-text


Available from: Junichiro Fujimoto, Apr 02, 2014
16 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary lymphoma of the central nervous system (PCNSL) is extremely rare, especially in childhood. A 9-year-old Japanese boy was diagnosed as having precursor-B cell-type lymphoblastic lymphoma, based on morphologic and immunocytochemical analysis of mononuclear cells in the cerebrospinal fluid and a positive reaction for terminal deoxynucleotidyl transferase (TdT), CD19, CD79a, and CD179b. After seven courses of chemotherapy and craniospinal radiotherapy, the patient is alive, well, and in continuous complete remission. Despite its rarity, PCNSL should be included in the differential diagnosis in the presence of symptoms of increased intracranial pressure and/or unusual imaging findings of the brain.
    Journal of Pediatric Hematology/Oncology 11/2005; 27(10):561-4. DOI:10.1097/01.mph.0000184570.70222.c5 · 0.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Precursor B-cell lymphoblastic lymphoma (B-LBL) is a rare neoplasm composed of immature lymphocytes that demonstrate lymphoblastic morphology and express precursor and B-cell marker. It usually affects people of younger age group and causes multiple nodules on the head and neck area. The neoplasm is rare in old age. We report a case of B-LBL occurring in a 65-year-old man. He presented with multiple skin nodules on the scalp, the neck and the arm for 2 months. Histopathologic examination demonstrated diffuse dermal and subcutaneous monotonous infiltrates of medium-sized lymphoid cells with starry-sky pattern. Immunohistochemical study showed that the lymphoid cells of infiltrate showed precursor B-cell type. The patient has received combination chemotherapy three times and is being followed-up at the outpatient clinic.
    Journal of Cutaneous Pathology 10/2006; 33(9):649-53. DOI:10.1111/j.1600-0560.2006.00405.x · 1.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Understanding of the pathogenesis and biology of precursor T-cell and B-cell neoplasms has advanced significantly with the description of gene expression profiling studies, especially in T-cell disease. These studies have demonstrated leukemic arrest at various stages of thymocyte maturation, characterized by gene expression signatures with prognostic significance. Optimal treatment strategies for adult lymphoblastic lymphoma are uncertain, although current evidence supports the use of regimens similar to those used in acute lymphoblastic leukemia, with intensive induction therapy, central nervous system prophylaxis, and prolonged consolidation maintenance therapy. Current studies do not demonstrate a benefit from stem cell transplantation in first remission, although this approach is probably beneficial in relapsed disease. Identification of new therapeutic targets by further molecular studies is required.
    Current Hematologic Malignancy Reports 12/2006; 1(4):241-7. DOI:10.1007/s11899-006-0005-8 · 2.20 Impact Factor
Show more